{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:07:10Z","timestamp":1791288430381,"version":"4.3.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82374423"],"award-info":[{"award-number":["82374423"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82474221"],"award-info":[{"award-number":["82474221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Liaoning Province Science and Technology Plan Joint Program (Natural Science Foundation - Surface Project","award":["2024-MSLH-290"],"award-info":[{"award-number":["2024-MSLH-290"]}]},{"name":"the Education fund item of Liaoning province","award":["LJ222410162041"],"award-info":[{"award-number":["LJ222410162041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic steatohepatitis (NASH) is a complex metabolic disorder with limited effective treatments, and its pathogenesis involves intricate crosstalk between gut microbiota, metabolism, and host signaling. Yinchenhaotang plus Zexietang (YCHZX), a traditional Chinese medicine (TCM) formulation, exhibits therapeutic potential in NASH, but its underlying mechanism\u2014especially its interactions with the gut microbiota and metabolic networks\u2014remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A NASH mouse model was established via a high-fat\/high-fructose\/high-cholesterol diet. Mice were treated with YCHZX or its individual components (YCH, ZX). Serum biochemistry and liver histopathology were used to evaluate systemic therapeutic effects. Integrated multi-omics analyses (16S rRNA microbiome, serum metabolomics, colon transcriptomics) combined with immunofluorescence, immunohistochemistry, RT\u2012qPCR and ELISA were employed to explore regulatory networks. Complementarily, the effects of sodium butyrate and indolelactic acid (ILA) were investigated using an LPS-stimulated Caco-2 cell model. Antibiotic-mediated gut microbiota ablation was performed to verify microbiota dependency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      YCHZX outperformed YCH and ZX in improving TC, LDL-C and hepatic pathology. Integrated multi-omics analysis demonstrated that the efficacy of YCHZX was associated with a distinct restructuring of the gut microbiota, specifically enriching butyrate-producing genera such as\n                      <jats:italic>Lachnospiraceae_NK4A136_group<\/jats:italic>\n                      . Concomitantly, YCHZX intervention suppressed colonic indoleamine 2,3-dioxygenase 1 (IDO1) and significantly elevated serum levels of ILA, a shift validated in vitro by the direct inhibitory effect of sodium butyrate on IDO1. The elevated ILA was shown to strengthen the gut barrier by upregulating occludin expression in LPS-stimulated Caco-2 cells via an aryl hydrocarbon receptor (AhR)-dependent mechanism. Further, YCHZX activated the AhR, upregulating tight-junction proteins (occludin) to reduce lipopolysaccharide (LPS) translocation, and inhibiting hepatic LPS\/TLR4 signaling, TG accumulation, and IL-1\u03b2 inflammation. All these effects of YCHZX were diminished by antibiotic-induced gut microbiota depletion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings demonstrate that YCHZX alleviates NASH in a gut microbiota-dependent manner. We propose a mechanism whereby YCHZX enriches butyrate-producing bacteria, which is associated with the suppression of colonic IDO1 and a shift in tryptophan metabolism toward ILA production. The increased ILA, in turn, contributes to the activation of the AhR, thereby restoring gut barrier integrity and mitigating liver inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-025-01304-w","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:15:07Z","timestamp":1768976107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multi-omics reveals an association of the gut butyrate-IDO1-tryptophan axis with Yinchenhaotang plus Zexietang-ameliorated NASH in a microbiota-dependent manner"],"prefix":"10.1186","volume":"21","author":[{"given":"Weimeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianqun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyuan","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"6","key":"1304_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2024.103043","volume":"55","author":"E Amini-Salehi","year":"2024","unstructured":"Amini-Salehi E, Letafatkar N, Norouzi N, Joukar F, Habibi A, Javid M, et al. Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries. Arch Med Res. 2024;55(6):103043. https:\/\/doi.org\/10.1016\/j.arcmed.2024.103043.","journal-title":"Arch Med Res"},{"issue":"Suppl","key":"1304_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","volume":"29","author":"SK Han","year":"2023","unstructured":"Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: definition and subtypes. Clin Mol Hepatol. 2023;29(Suppl):S5\u201316. https:\/\/doi.org\/10.3350\/cmh.2022.0424.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"1304_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223\u201338. https:\/\/doi.org\/10.1038\/s41575-020-00381-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1304_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.02.021","volume":"81","author":"Z Lu","year":"2024","unstructured":"Lu Z, Shao W, Song J. The transition from NAFLD to MASLD and its impact on clinical practice and outcomes. J Hepatol. 2024;81(4):e155-e156. https:\/\/doi.org\/10.1016\/j.jhep.2024.02.021.","journal-title":"J Hepatol"},{"issue":"4","key":"1304_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69(4):896\u2013904. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.036.","journal-title":"J Hepatol"},{"issue":"10","key":"1304_CR6","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","volume":"9","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Shang Y, Hegmar H, Nasr P. Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol. 2024;9(10):944\u201356. https:\/\/doi.org\/10.1016\/S2468-1253(24)00193-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1304_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105484","volume":"167","author":"N Sodum","year":"2021","unstructured":"Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD\/NASH: targets and therapy. Pharmacol Res. 2021;167:105484. https:\/\/doi.org\/10.1016\/j.phrs.2021.105484.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1304_CR8","doi-asserted-by":"publisher","first-page":"2500099","DOI":"10.1080\/19490976.2025.2500099","volume":"17","author":"H Wu","year":"2025","unstructured":"Wu H, Chen J, Guo S, Deng J, Zhou Z, Zhang X, et al. Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease. Gut Microbes. 2025;17(1):2500099. https:\/\/doi.org\/10.1080\/19490976.2025.2500099.","journal-title":"Gut Microbes"},{"issue":"7","key":"1304_CR9","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1053\/j.gastro.2022.01.058","volume":"162","author":"KC Bauer","year":"2022","unstructured":"Bauer KC, Littlejohn PT, Ayala V, Creus-Cuadros A, Finlay BB. Nonalcoholic fatty liver disease and the gut-liver axis: exploring an undernutrition perspective. Gastroenterology. 2022;162(7):1858-1875.e2. https:\/\/doi.org\/10.1053\/j.gastro.2022.01.058.","journal-title":"Gastroenterology"},{"issue":"6","key":"1304_CR10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.chom.2025.04.020","volume":"33","author":"X Luo","year":"2025","unstructured":"Luo X, Wang K, Jiang C. Gut microbial enzymes and metabolic dysfunction-associated steatohepatitis: function, mechanism, and therapeutic prospects. Cell Host Microbe. 2025;33(6):836\u201353. https:\/\/doi.org\/10.1016\/j.chom.2025.04.020.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"1304_CR11","doi-asserted-by":"publisher","first-page":"2307568","DOI":"10.1080\/19490976.2024.2307568","volume":"16","author":"BH Min","year":"2024","unstructured":"Min BH, Devi S, Kwon GH, Gupta H, Jeong JJ, Sharma SP, et al. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. Gut Microbes. 2024;16(1):2307568. https:\/\/doi.org\/10.1080\/19490976.2024.2307568.","journal-title":"Gut Microbes"},{"issue":"11","key":"1304_CR12","first-page":"964","volume":"32","author":"XY Liu","year":"2022","unstructured":"Liu XY, Ma SP, Zhang LH, Zhao WX. Professor Zhao Wenxia\u2019s experience in treating non-alcoholic fatty liver disease with\"four discriminations\"and \u201cfour differentiations.\u201d Chin j integr tradit west med liver dis. 2022;32(11):964\u20138.","journal-title":"Chin j integr tradit west med liver dis"},{"issue":"22","key":"1304_CR13","first-page":"145","volume":"18","author":"ZY Nie","year":"2021","unstructured":"Nie ZY, Feng Cl, Pan WY, Liu J, Liang WH, Luo MT, et al. Feng Chonglian\u2019s experience in the syndrome differentiation and treat-ment of non-alcoholic fatty liver disease. Chin med herald. 2021;18(22):145\u20138.","journal-title":"Chin med herald"},{"issue":"11","key":"1304_CR14","first-page":"805","volume":"25","author":"Chinese Association of Integrated Traditional and Western Medicine digestive diseases professional committee","year":"2017","unstructured":"Chinese Association of Integrated Traditional and Western Medicine digestive diseases professional committee. Consensus opinions on the diagnosis and treatment of non-alcoholic fatty liver disease with integrated Chinese and Western medicine. Chin j integr tradit west med liver dis. 2017;25(11):805\u201311.","journal-title":"Chin j integr tradit west med liver dis"},{"issue":"1","key":"1304_CR15","first-page":"1","volume":"13","author":"Diagnosis and Treatment Center of Hepatology of South China Alliance of TCM, National Administration of Traditional Chinese Medicine","year":"2018","unstructured":"Diagnosis and Treatment Center of Hepatology of South China Alliance of TCM, National Administration of Traditional Chinese Medicine. Diagnosis and treatment scheme of Ganpi (non-alcoholic steatohepatitis). Chin J Liver Dis (Electronic Version). 2018;13(1):1\u20139.","journal-title":"Chin J Liver Dis (Electronic Version)"},{"key":"1304_CR16","unstructured":"Zhang. Z. Shang Han Lun (Treatise on Cold Damage Diseases). c. 200\u2013210 AD."},{"key":"1304_CR17","unstructured":"Li. S.Z. Ben Cao Gang Mu (Compendium of Materia Medica). 1596 AD."},{"key":"1304_CR18","unstructured":"Zhang. Z. Jin Gui Yao Lue (Synopsis of the Golden Chamber). c. 200\u2013210 AD."},{"issue":"02","key":"1304_CR19","first-page":"80","volume":"27","author":"D Liu","year":"2017","unstructured":"Liu D, Li P, Wang JL, Jiang ZL, Li S. Clinical study on effect of Yinchenhao Decoction in treating nonalcoholic fatty liver diseases and the influence of the expression of TLR-4. Chin j integr tradit west med liver dis. 2017;27(02):80\u20132.","journal-title":"Chin j integr tradit west med liver dis"},{"key":"1304_CR20","doi-asserted-by":"publisher","unstructured":"Lu. XL. 2020. Study on the Mechanism of Alisma Decoction Intervening with NASH Liver Fibrosis through Anti-oxidative Stress of Nrf2 Pathway. Shanghai University of Traditional Chinese Medicine. https:\/\/doi.org\/10.27320\/d.cnki.gszyu.2020.000220.","DOI":"10.27320\/d.cnki.gszyu.2020.000220"},{"issue":"06","key":"1304_CR21","first-page":"1699","volume":"27","author":"XY Sha","year":"2025","unstructured":"Sha XY, Huang YY, Liu BY, Yang SQ, Jia LQ, Sui GY. Effects of Yinchenhao Decoction plus Zexie Decoction on ferroptosis mediated by IRE1 signaling pathway of endoplasmic reticulum stress in NASH mice. Modern Tradit Chin Med Materia Medica-World Sci Technol. 2025;27(06):1699\u2013708.","journal-title":"Modern Tradit Chin Med Materia Medica-World Sci Technol"},{"key":"1304_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jpba.2019.06.028","volume":"174","author":"F Liu","year":"2019","unstructured":"Liu F, Sun Z, Hu P, Tian Q, Xu Z, Li Z, et al. Determining the protective effects of Yin-Chen-Hao Tang against acute liver injury induced by carbon tetrachloride using 16S rRNA gene sequencing and LC\/MS-based metabolomics. J Pharm Biomed Anal. 2019;174:567\u201377. https:\/\/doi.org\/10.1016\/j.jpba.2019.06.028.","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"1304_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ph18070932","volume":"18","author":"W Li","year":"2025","unstructured":"Li W, Huang D, Luo Z, Zhou T, Jin Z. Yinchenhao decoction mitigates cholestatic liver injury in mice via gut microbiota regulation and activation of FXR-FGF15 pathway. Pharmaceuticals (Basel). 2025;18(7):932.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1304_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.118700","volume":"337","author":"J Shi","year":"2025","unstructured":"Shi J, Liu Y, Zhang Z, Zhong X, Cao Y, Ni H, et al. Zexie-Baizhu decoction ameliorates non-alcoholic fatty liver disease through gut-adipose tissue crosstalk. J Ethnopharmacol. 2025;337(1):118700. https:\/\/doi.org\/10.1016\/j.jep.2024.118700.","journal-title":"J Ethnopharmacol"},{"key":"1304_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bbrc.2022.09.097","volume":"632","author":"F Zhang","year":"2022","unstructured":"Zhang F, Wu J, Ruan H, Xia J, Xue H, Wang J, et al. Zexie decoction alleviates non-alcoholic fatty liver disease in rats: the study of genes, lipids, and gut microbiotas. Biochem Biophys Res Commun. 2022;632:129\u201338. https:\/\/doi.org\/10.1016\/j.bbrc.2022.09.097.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1304_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12876-020-01356-2","volume":"20","author":"HH Hansen","year":"2020","unstructured":"Hansen HH, \u00c6gidius HM, Or\u00f3 D, Evers SS, Heeb\u00f8ll S, Eriksen PL, et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 2020;20(1):210. https:\/\/doi.org\/10.1186\/s12876-020-01356-2.","journal-title":"BMC Gastroenterol"},{"key":"1304_CR27","volume-title":"Clinical pharmacology experimental methodology","author":"RC Guo","year":"2012","unstructured":"Guo RC. Clinical pharmacology experimental methodology. Beijing: People\u2019s Medical Publishing House; 2012."},{"issue":"6","key":"1304_CR28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1053\/j.gastro.2023.08.052","volume":"165","author":"H Gou","year":"2023","unstructured":"Gou H, Su H, Liu D, Wong CC, Shang H, Fang Y, et al. Traditional medicine Pien Tze Huang suppresses colorectal tumorigenesis through restoring gut microbiota and metabolites. Gastroenterology. 2023;165(6):1404\u201319.","journal-title":"Gastroenterology"},{"issue":"3","key":"1304_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jhep.2016.05.005","volume":"65","author":"A Asgharpour","year":"2016","unstructured":"Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016;65(3):579\u201388. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.005.","journal-title":"J Hepatol"},{"issue":"4","key":"1304_CR30","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1021\/acs.jafc.2c06894","volume":"71","author":"Q Cui","year":"2023","unstructured":"Cui Q, Zhang Z, Tian X, Liang X, Lu Y, Shi Y, et al. Bifidobacterium bifidum ameliorates DSS-induced colitis in mice by Regulating AHR\/NRF2\/NLRP3 inflammasome pathways through Indole-3-lactic acid production. J Agric Food Chem. 2023;71(4):1970\u201381. https:\/\/doi.org\/10.1021\/acs.jafc.2c06894.","journal-title":"J Agric Food Chem"},{"key":"1304_CR31","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.3389\/fimmu.2018.02838","volume":"9","author":"C Martin-Gallausiaux","year":"2018","unstructured":"Martin-Gallausiaux C, Larraufie P, Jarry A, B\u00e9guet-Crespel F, Marinelli L, Ledue F, et al. Butyrate produced by commensal bacteria down-regulates indolamine 2,3-dioxygenase 1 (IDO-1) expression via a dual mechanism in human intestinal epithelial cells. Front Immunol. 2018;9:2838. https:\/\/doi.org\/10.3389\/fimmu.2018.02838.","journal-title":"Front Immunol"},{"key":"1304_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/art.43430","author":"L Wu","year":"2025","unstructured":"Wu L, Zhang Q, Tang Z, Li Y, Wu T, Chen L, et al. Gut microbiota-derived tryptophan indole metabolites ameliorate collagen-induced arthritis in mice via aryl hydrocarbon receptor activation in T cells and intestinal epithelial cells. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43430.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1304_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ptr.8027","volume":"38","author":"X Wang","year":"2024","unstructured":"Wang X, Xie X, Li Y, Xie X, Huang S, Pan S, et al. Quercetin ameliorates ulcerative colitis by activating aryl hydrocarbon receptor to improve intestinal barrier integrity. Phytother Res. 2024;38(1):253\u201364. https:\/\/doi.org\/10.1002\/ptr.8027.","journal-title":"Phytother Res"},{"issue":"3","key":"1304_CR34","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810\u201320. https:\/\/doi.org\/10.1002\/hep.24127.","journal-title":"Hepatology"},{"issue":"44","key":"1304_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi7337","volume":"9","author":"S Huang","year":"2023","unstructured":"Huang S, Chen J, Cui Z, Ma K, Wu D, Luo J, et al. Lachnospiraceae-derived butyrate mediates protection of high fermentable fiber against placental inflammation in gestational diabetes mellitus. Sci Adv. 2023;9(44):eadi7337. https:\/\/doi.org\/10.1126\/sciadv.adi7337.","journal-title":"Sci Adv"},{"issue":"1","key":"1304_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40168-023-01606-x","volume":"11","author":"P Sun","year":"2023","unstructured":"Sun P, Wang M, Liu YX, Li L, Chai X, Zheng W, et al. High-fat diet-disturbed gut microbiota-colonocyte interactions contribute to dysregulating peripheral tryptophan-kynurenine metabolism. Microbiome. 2023;11(1):154. https:\/\/doi.org\/10.1186\/s40168-023-01606-x.","journal-title":"Microbiome"},{"issue":"52","key":"1304_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2412070121","volume":"121","author":"H Wang","year":"2024","unstructured":"Wang H, Xu F, Yao C, Dai H, Xu J, Wu B, et al. Engineering bacteria for cancer immunotherapy by inhibiting IDO activity and reprogramming CD8+ T cell response. Proc Natl Acad Sci U S A. 2024;121(52):e2412070121. https:\/\/doi.org\/10.1073\/pnas.2412070121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1304_CR38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s40168-024-01896-9","volume":"12","author":"S Zhang","year":"2024","unstructured":"Zhang S, Nie Q, Sun Y, Zuo S, Chen C, Li S, et al. Bacteroides uniformis degrades \u03b2-glucan to promote Lactobacillus johnsonii improving indole-3-lactic acid levels in alleviating colitis. Microbiome. 2024;12(1):177. https:\/\/doi.org\/10.1186\/s40168-024-01896-9.","journal-title":"Microbiome"},{"key":"1304_CR39","first-page":"26","volume":"7","author":"MS Yin","year":"2024","unstructured":"Yin MS, Wang Y, Li Z, Wang SQ, Yin HJ, Da HY, et al. Review and reflection on the development of new drugs for non-alcoholic steatohepatitis. China Food & Drug Administration Magazine. 2024;7:26\u201335.","journal-title":"China Food & Drug Administration Magazine"},{"issue":"8","key":"1304_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41577-024-01014-8","volume":"24","author":"ER Mann","year":"2024","unstructured":"Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. 2024;24(8):577\u201395. https:\/\/doi.org\/10.1038\/s41577-024-01014-8.","journal-title":"Nat Rev Immunol"},{"key":"1304_CR41","unstructured":"Jiannan Qiu. Effect mechanism of Yinchenhao Decoction and its components in regulating MAFLD Based on Diversity of Gut microbiota and Metabolomics. Shanghai University of Traditional Chinese Medicine. 2020."},{"key":"1304_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1107071","volume":"13","author":"D Hui","year":"2023","unstructured":"Hui D, Liu L, Azami NLB, Song J, Huang Y, Xu W, et al. The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial. Front Endocrinol (Lausanne). 2023;13:1107071. https:\/\/doi.org\/10.3389\/fendo.2022.1107071.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1304_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117156","volume":"178","author":"C Sun","year":"2024","unstructured":"Sun C, Xiong X, Liu M, Liang Q, Zhao Q, Wei G, et al. Bacteroides ovatus alleviates high-fat and high-cholesterol -induced nonalcoholic fatty liver disease via gut-liver axis. Biomed Pharmacother. 2024;178:117156. https:\/\/doi.org\/10.1016\/j.biopha.2024.117156.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"1304_CR44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41591-018-0060-4","volume":"24","author":"L Laurans","year":"2018","unstructured":"Laurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, et al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat Med. 2018;24(8):1113\u201320. https:\/\/doi.org\/10.1038\/s41591-018-0060-4.","journal-title":"Nat Med"},{"issue":"5","key":"1304_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05853-6","volume":"14","author":"A Sarkar","year":"2023","unstructured":"Sarkar A, Mitra P, Lahiri A, Das T, Sarkar J, Paul S, et al. Butyrate limits inflammatory macrophage niche in NASH. Cell Death Dis. 2023;14(5):332. https:\/\/doi.org\/10.1038\/s41419-023-05853-6.","journal-title":"Cell Death Dis"},{"key":"1304_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156791","volume":"142","author":"BX Zheng","year":"2025","unstructured":"Zheng BX, Yi Y, Wang XW, Li CY, Zhao Y, Tian JZ, et al. Geniposide via enema alleviates colitis by modulating intestinal flora and bile acid metabolites, inhibiting S100A8\/S100A9\/NF-\u03baB, and promoting TGR5 inhibition of NLRP3 inflammasome. Phytomedicine. 2025;142:156791. https:\/\/doi.org\/10.1016\/j.phymed.2025.156791.","journal-title":"Phytomedicine"},{"issue":"10","key":"1304_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240616","volume":"15","author":"X Xu","year":"2020","unstructured":"Xu X, Li L, Zhang Y, Lu X, Lin W, Wu S, et al. Hypolipidemic effect of Alisma orientale (Sam.) Juzep on gut microecology and liver transcriptome in diabetic rats. PLoS ONE. 2020;15(10):e0240616. https:\/\/doi.org\/10.1371\/journal.pone.0240616.","journal-title":"PLoS ONE"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01304-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01304-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01304-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:15:11Z","timestamp":1768976111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-025-01304-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1304"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01304-w","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiment was conducted with the approval of the Experimental Animal Ethics Committee of Liaoning University of Traditional Chinese Medicine with ethics review numbers 2021000042022098.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to the publication of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}